According to a new report published by Introspective Market Research, titled, Non-Invasive Blood Glucose Monitoring Device Market by Type, Technology, Application, End-User, Distribution Channel, and Region, Global Industry Analysis and Forecast, 2024-2032. The Global Non-Invasive Blood Glucose Monitoring Device Market was valued at US$ 26.19 Million in 2023 and is expected to reach US$ 177.22 Million by the year 2032, at a CAGR of 23.67%. The worldwide Non-invasive Blood Glucose Monitoring Devices market includes the creation, production, and distribution of medical equipment that gauges glucose levels without using invasive techniques like finger pricks. Technologies like optical sensors, microneedles, and transdermal biosensors allow for real-time glucose monitoring with little discomfort. As of 2023, more than 557 million individuals are impacted by diabetes, leading to increased market growth driven by the need for convenient solutions. Technological progress and regulatory backing are enhancing diabetes management and adherence, revolutionizing the approach to this condition.
According to the non-invasive blood glucose monitoring device market is segmented into type, technology, application, end-user, distribution channel, and region. By Type, the market is categorized into Wearable Devices, Portable Devices, Stationary Devices, Breath Analysis Devices, and Transdermal Devices. By Technology, the market is categorized into Optical Technologies and Electromagnetic & Electric Techniques. By Application, the market is categorized into Diabetes Monitoring, Pre-Diabetes Monitoring, Gestational Diabetes Monitoring, and Others. By End-User, the market is categorized into Hospitals & Clinics, Home Care Settings, Clinical Research Organizations, and Fitness Centers & Gyms. By Application, the market is categorized into Direct Sales, Healthcare Facilities, Pharmacies, and Online Sales. By Region, it is analyzed across North America (U.S.; Canada; Mexico), Eastern Europe (Bulgaria; The Czech Republic; Hungary; Poland; Romania; Rest of Eastern Europe), Western Europe (Germany; UK; France; Netherlands; Italy; Russia; Spain; Rest of Western Europe), Asia-Pacific (China; India; Japan; Southeast Asia, etc.), South America (Brazil; Argentina, etc.), Middle East & Africa (Saudi Arabia; South Africa, etc.).
The increasing global elderly population notably fuels the need for non-invasive blood glucose monitoring devices, especially in the U.S. and China. In 2023, the U.S. documented 231,361 people under 55, making up 70% of the population, whereas those between 55-64 comprised a notable portion. China's senior population is significant, consisting of 216.8 million individuals aged 65 and above, making up 15.4% of the total population. Diabetes is a significant issue, with 21.3% of the EU population being 65 or older, underscoring the necessity for efficient treatment. Easy-to-use, non-intrusive devices are crucial for seniors who find traditional methods daunting, suggesting an expanding market opportunity to improve the quality of life for older individuals, particularly as Germany's elderly demographic is projected to increase significantly by 2050.
Data analytics and AI are transforming the non-invasive blood glucose monitoring industry, driving innovation in response to increasing personalized healthcare needs. AI devices such as Actxa's BGEM employ cloud-based algorithms for continuous glucose monitoring through non-invasive sensors, delivering real-time data for the early identification of abnormalities and prompt interventions. Through the examination of vast health information and glucose trends, these technologies improve preventive care and health administration. Devices powered by AI that use photoplethysmography (PPG) sensors enhance both precision and ease compared to conventional finger-stick tests. With the progress of AI, it improves early detection and prevention of health risks, boosting the efficacy of non-invasive glucose monitoring as diabetes rates rise, featuring accessible tools such as SugarBEAT and UBand.
Non-Invasive Blood Glucose Monitoring Device Market Segmentation
Non-Invasive Blood Glucose Monitoring Device Market is segmented on the basis of Type, Technology, Application, End-User, Distribution Channel, and Region
By Technology:
The Optical Technologies sector is poised to lead the Non-Invasive Blood Glucose Monitoring Device market because of its precise and pain-free glucose monitoring features. Methods such as near-infrared and Raman spectroscopy enable non-invasive assessments via light interactions with tissues, improving patient comfort. Advancements in optical sensors have enhanced precision and dependability, leading to their increasing popularity among consumers and medical professionals. Moreover, the low cost and ease of transport of these devices, along with their capability to decrease healthcare expenses, bolster their expansion, establishing optical technologies as a key market participant.
By Type:
In 2023, the Wearable Devices category dominated the Glucose Monitoring Device Market with a 39.03% share, fuelled by increasing demand for continuous glucose monitoring (CGM) systems. These tools enable real-time glucose monitoring and minimize finger-prick testing, attracting especially younger, technology-oriented individuals and those requiring active diabetes management. The rise in diabetes cases and advancements in technology enhance adoption. Wearable devices aid customized healthcare by providing practical insights and better glycemic management, while their compatibility with fitness trackers boosts usability. Heightened awareness and governmental efforts are expected to preserve this sector's leading position moving forward.
Region:
North America, including Canada, the United States, and Mexico, is set to lead the market throughout the forecast period. At present, the population is approximately 615 million, with the U.S. accounting for nearly 57%. Between 2016 and 2024, the population increased from 565 million to more than 613 million, with an expectation to hit 713.7 million by 2083. Prominent cities such as New York and Mexico City contribute significantly to the economy of this affluent area. The U.S. leads in technology and finance, whereas Canada and Mexico provide resources and engage in trade. Nonetheless, health issues remain, especially with a 14% diabetes rate projected to increase to 24% by 2045, affecting expenses and death rates.
Some of The Active Market Players Are-
- Aerbetic (U.S.)
- Afon Technology (United Kingdom)
- Bobang Fangzhou Medical Technology (Beijing) Co., Ltd. (China)
- Cnoga (Israel)
- Diamontech Ag (Germany)
- Eyva (India)
- Glucorx Limited (United Kingdom)
- Hagar (Gwave) (Israel)
- Know Labs, Inc. (U.S.)
- Lifeplus (U.S.)
- Liom (Switzerland)
- Mimos Berhad (Malaysia)
- Nemaura Medical (U.S)
- Noviosense Bv (Netherland)
- Occuity (United Kingdom)
- Pkvitality (France)
- Quantum Operation Inc. (Japan)
- Rsp System (Denmark)
- Shinsei Corporation (Japan)
- Sibionics (China), Other Active Players
Key Industry Developments
- In December 2024, Liom, formerly Spiden, announced significant progress in non-invasive glucose monitoring, achieving accurate glucose measurements without invasive calibration. In 2024, the company demonstrated a MARD of 14.5%, with potential for further improvement. Liom raised over USD 55m in funding and secured over USD 25m in its Series A. The company plans to develop a wrist-worn prototype for testing by 2025 and aims for a product launch by mid-2027. Liom’s technology aims to revolutionize health monitoring with light- and AI-driven wearables.
- In April 2023, MIMOS, Malaysia's applied research agency, launched GlucoSenz, a non-invasive blood glucose monitor, after seven years of development. The device used chemometric methods and photonics technology to analyze near-infrared absorbances from a user’s thumb, eliminating the need for finger-pricking. Expected to reach the public by year-end 2024, GlucoSenz promises improved safety for healthcare workers.
Key Findings of the Study:
- Optical technologies dominate the market with precise, pain-free glucose monitoring, driven by innovations in near-infrared and Raman spectroscopy
- Wearable devices held a 39.03% share in 2023, driven by rising demand for real-time monitoring and integration with fitness trackers.
- North America leads the market due to advanced healthcare infrastructure, high diabetes prevalence, and a growing elderly population.
- AI and data analytics enhance glucose monitoring precision and usability, enabling personalized healthcare and preventive care solutions.